Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 3 - Drugs for disorders of the metabolism
Patents for A61P 3 - Drugs for disorders of the metabolism (129,789)
04/2003
04/02/2003CN1407969A Process for the preparation of oxyiminoalkanoic acid derivatives
04/02/2003CN1407897A DHEA composition and method
04/02/2003CN1406940A Chlorophyll chromium and preparation and use thereof
04/02/2003CN1406627A Superfine powder of Tangniaokang against diabetic and preparing process
04/02/2003CN1406623A Levulose absorption retardant, compound, food and levulose absorption repressor
04/02/2003CN1406622A High efficiency weight reduction medicine or health-care food
04/02/2003CN1406587A Use of activated carbon in oral medicinal preparation for hyperthyroidism
04/02/2003CN1406523A Oral liquid production
04/02/2003CN1406515A Health-care food or medicine for reducing blood sugar
04/02/2003CN1104432C Pyrrole triazines and pyrimidine compound
04/02/2003CN1104421C Novel imino derivatives as inhibitors of bone resorption and vitronectin receptor antagonists
04/02/2003CN1104418C Benzoheterocyclic derivatives
04/02/2003CN1104253C Medicine for strengthening physique and strengthening immunity
04/02/2003CN1104252C Health-care oil for reducing cholesterol and its preparing process
04/02/2003CA2424540A1 Propionic acid derivatives with ppar-alpha activating properties
04/01/2003US6541638 (2S,4S)-1-(4-Mercapto-1-(naphthalene-2-sulfonyl)-pyrrolidine-2 -carbonyl)-piperidine-4-carboxylic acid ethyl ester for example; zinc protease inhibitors; for treating diseases associated with vasoconstriction
04/01/2003US6541623 Sepsis shock therapy; rheumatic diseases; antiinflammatory agents; nucleotide sequence detector
04/01/2003US6541522 Including longistyline A-2-carboxylic acid as a dietary supplement
04/01/2003US6541511 Treatment and prophylaxis of hypercholesterolemia and of various cardiac disorders.
04/01/2003US6541503 Substituted oxindole derivatives as protein tyrosine kinase and as protein serine/threonine kinase inhibitors
04/01/2003US6541493 Type A, B, C and D crystals of said compound; excellent in stability, and has advantages in handling, storage, and pharmaceutical preparation.
04/01/2003US6541492 Thiazole derivatives as PPAR gamma ligands
04/01/2003US6541469 CRF receptor antagonists and methods relating thereto
04/01/2003US6541049 Method for production of arachidonic acid
04/01/2003US6541046 Herbal composition and method for controlling body weight and composition
04/01/2003US6541033 Thermosensitive biodegradable hydrogels for sustained delivery of leptin
04/01/2003US6541026 Nutritional composition, methods of producing said composition and methods of using said composition
04/01/2003US6541006 Administration in a daily dose to a patient for reducing or controlling blood high density lipoproteins, a formulation containing between 50mg to 3.6 gm. red yeast rice, 5mg-600 mg coenzyme Q10 and between 5 IU to 800 IU mixed tocopherols
04/01/2003US6541005 Compositions and methods for reducing or controlling blood cholesterol, lipoproteins, triglycerides and atherosclerosis
04/01/2003US6540983 A drug selected from an insulin analog, and/or amylin, a fluid propellant carrier, and a stabilizer comprising water added in addition to nascent formulation water; treating diabetes; inhalers
04/01/2003US6540982 Medical aerosol formulation
04/01/2003CA2102129C Growth hormone antagonists
03/2003
03/31/2003WO2002030425A1 Preventives and remedies for complications of diabetes
03/31/2003CA2424060A1 Preventives and remedies for complications of diabetes
03/28/2003CA2405342A1 Methods of treatment and kits comprising a growth hormone secretagogue
03/28/2003CA2404723A1 Methods related to the a-c repeat z-sequence upstream from the aldose reductase gene
03/27/2003WO2003025542A2 Immune response associated proteins
03/27/2003WO2003025199A2 Mid 4460, a human tyrosine phosphatase family member and uses therefor
03/27/2003WO2003025168A1 Novel protein and dna thereof
03/27/2003WO2003025150A2 Lipid-associated molecules
03/27/2003WO2003025131A2 Protein modification and maintenance molecules
03/27/2003WO2003025129A2 Neurotransmission-associated proteins
03/27/2003WO2003025121A2 Igf-binding protein-derived peptide or small molecule
03/27/2003WO2003025014A2 Use of peptides comprising post-translational modifications in the treatment of autoimmune pathologies
03/27/2003WO2003024976A2 Tricyclic indole derivatives as 5-ht ligands
03/27/2003WO2003024966A1 Pteridinone derivatives as modulators of chemokine receptor activity
03/27/2003WO2003024965A2 Heterocyclic compounds that are inhibitors of the enzyme dpp-iv
03/27/2003WO2003024953A1 Propanolamine derivative having 1,4-benzodioxane ring
03/27/2003WO2003024952A1 Bioprecursors for percutaneous application
03/27/2003WO2003024948A1 Benzofuran and dihydrobenzofuran derivatives useful as beta-3 adrenoreceptor agonists
03/27/2003WO2003024946A2 Oxamate derivatives containing a variously substituted nitrogen heterocycle
03/27/2003WO2003024943A2 Aryl derivatives for the treatment of diabetes, hyperlipidemia, hypercholesterolemia and atherosclerosis
03/27/2003WO2003024942A1 Thiazolidine derivative and medicinal use thereof
03/27/2003WO2003024937A1 Benzimidazolylalkoxyaryl alkanoic acid derivatives and their use as antihyperglycemics
03/27/2003WO2003024929A1 Substituted piperidines with selective binding to histamine h3-receptor
03/27/2003WO2003024928A2 Novel aminoazetidine, -pyrrolidine and -piperidine derivatives
03/27/2003WO2003024913A1 SUBSTITUTED BENZOIC ACID DERIVATIVES EXHIBITING NF-κB INHIBITING ACTIVITY
03/27/2003WO2003024485A1 REMEDIES FOR DISEASES CAUSED BY β-AMYLOIDS CONTAINING 2-100β INHIBITOR AS THE ACTIVE INGREDIENT
03/27/2003WO2003024479A1 Enamel matrix protein compositions for modulating immune response
03/27/2003WO2003024474A2 Anti-inflammatory agent
03/27/2003WO2003024468A1 Substances extracted from corn which can inhibit the activities of amylase, pharmaceutical compositions and food additives containing the same extracts for treatment or prevention of obesity and diabetes mellitus, and processes for their preparations
03/27/2003WO2003024467A1 Compositions containing specific plants and drugs and foods for health use comprising the compositions as the active ingredient
03/27/2003WO2003024447A1 Inhibitors of glycogen synthase kinase-3
03/27/2003WO2003024446A1 Oxidation stress inhibitor and method of measuring oxidation stress
03/27/2003WO2003024441A1 Novel use of tricyclic compound
03/27/2003WO2003024395A2 Linked biaryl compounds
03/27/2003WO2003024246A1 Compositions for appetite control and related methods
03/27/2003WO2003024245A1 Composition for reducing appetite in mammals comprising proxyanidin
03/27/2003WO2003024237A1 Oil composition
03/27/2003WO2003002553A3 Fluoropyrrolidines as dipeptidyl peptidase inhibitors
03/27/2003WO2003002149A3 Use of pigment such as e.g. titanium dioxide for obtaining a special optical effect on oral medicament or food
03/27/2003WO2003002058A8 Bone anabolic compounds and methods of use
03/27/2003WO2002098854A3 Process for preparing chiral diol sulfones and dihydroxy acid hmg coa reductase inhibitors
03/27/2003WO2002096358A3 Substituted azole acid derivatives useful as antidiabetic and antiobesity agents and method
03/27/2003WO2002094263A3 Caspase inhibitors and uses thereof
03/27/2003WO2002089781A3 Methods of treating hyperlipidemia
03/27/2003WO2002083870A3 Pufa polyketide synthase systems and uses thereof
03/27/2003WO2002053190A3 Particles for inhalation having sustained release properties
03/27/2003WO2002053100A3 Pharmaceutical dosage form for oral administration of low molecular weight heparin
03/27/2003WO2002034201A3 Use of pericyte apoptosis inhibitors for treating and/or preventing diabetic retinopathy
03/27/2003WO2002032416A3 Inhibition of emetic effect of metformin with 5-ht3 receptor antagonists
03/27/2003WO2002026774A3 Melanocortin receptor ligands
03/27/2003WO2002022684A3 Transporters and ion channels
03/27/2003WO2002012340A3 Transporters and ion channels
03/27/2003WO2002005857A3 Phosphatonin-related gene and methods of use thereof
03/27/2003WO2002000692A3 Pd-l2 molecules: pd-1 ligands and uses therefor
03/27/2003WO2001062954A3 Stearoyl-coa desaturase to identify triglyceride reducing therapeutic agents
03/27/2003US20030060873 Providing an electrochemical solution comprising metal and bioactive material; contacting electrochemical solution and substrate; forming a bioactive composite structure on substrate using an electrochemical procedure
03/27/2003US20030060695 Implantable artificial organ devices
03/27/2003US20030060633 Asymmetric synthesis of kavalactones
03/27/2003US20030060624 Reacting 2-chloro-4- trifluoromethyl-phenyl)-acetonitrile in the presence of a palladium catalyst and a base to form indene derivative
03/27/2003US20030060619 Antibody for use in the disgnosis and treatment of kidney, urogenital, and sex disorders
03/27/2003US20030060616 Type II IL-1 receptors
03/27/2003US20030060604 Apolipoprotein agonist for use in the treatment of dyslipidemia
03/27/2003US20030060498 5-arylsulfonyl indoles useful for treating disease
03/27/2003US20030060497 Use of indole Mannich bases in the production of medicaments that are used to treat pain
03/27/2003US20030060494 Dipeptidyl peptidase IV inhibiting agent; treatment of gastrointestinal disorders
03/27/2003US20030060491 Bicyclic aromatic compounds
03/27/2003US20030060487 Useful for treatments for peptide aggregation associated with disease state such as Alzhemimer's diseases
03/27/2003US20030060485 (+)-norcisapride
1 ... 918 919 920 921 922 923 924 925 926 927 928 929 930 931 932 933 934 935 936 937 938 ... 1298